EastGate Biotech Corp. (OTC: PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced today that it has filed an application with the Drug...
Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome Short bowel syndrome (SBS) is a complex chronic and severe condition associated with reduced or complete loss of...
Global 4WHIM trial marks first-ever Phase 3 study in patients with WHIM syndrome X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the...
SPI-1005 hits pre-specified endpoints resulting in a significant improvement in hearing loss of 65% and 95% relative to placebo Sound Pharmaceuticals today announced positive top-line results from a randomized, double-blind, placebo-controlled, multi-center...
Email
Text